

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF OHIO  
EASTERN DIVISION**

<b>IN RE: NATIONAL PRESCRIPTION</b>	)	<b>MDL 2804</b>
<b>OPIATE LITIGATION</b>	)	
	)	<b>Case No. 1:17-md-2804</b>
<b>THIS DOCUMENT RELATES TO:</b>	)	
	)	<b>Judge Dan Aaron Polster</b>
<i>ALL THIRD PARTY PAYOR ACTIONS</i>	)	

**AMENDED ORDER GRANTING THIRD PARTY PAYOR PLAINTIFFS’  
MOTION FOR (1) PRELIMINARY APPROVAL OF CLASS ACTION SETTLEMENT,  
AND (2) DIRECTION OF NOTICE UNDER FEDERAL RULE OF CIVIL PROCEDURE  
23(e)**

Before the Court is Third Party Payor (“TPP”) Plaintiffs’ Motion for (1) Preliminary Approval of Class Action Settlement and (2) Direction of Notice Under Federal Rule of Civil Procedure 23(e), which seeks: (i) Preliminary Approval of the Settlement Agreement; (ii) preliminary certification, for settlement purposes only, of the Settlement Class; (iii) appointment of Interim Settlement Class Counsel and Interim Co-Lead Settlement Class Counsel; (iv) appointment of Settlement Class Representatives; (v) approval of the Notice and proposed Notice Plan; (vi) scheduling of the Fairness Hearing, to occur after the conclusion of the notice period; (vii) appointment of the Notice and Claims Administrator; and (viii) an order staying and enjoining Actions against Teva, including its subsidiaries and affiliates, as set forth below.

WHEREAS, a proposed Class Action Settlement Agreement (the “Settlement”) has been reached between Class Counsel for TPP Plaintiffs, on behalf of a proposed settlement class of TPPs, and Teva<sup>1</sup> that resolves certain claims against Teva pertaining to its manufacture, marketing, and distribution of opioids and alleged contribution to the opioid epidemic;

WHEREAS, the Court, for purposes of this Order, adopts all defined terms as set forth in the Settlement Agreement attached as Exhibit C to the Joint Declaration of Paul J. Geller and Elizabeth J. Cabraser (ECF 6600-1), unless otherwise defined herein;

WHEREAS, Teva does not oppose the Court’s entry of the proposed Preliminary Approval Order;

WHEREAS, this Court has presided over and managed these MDL proceedings since the United States Judicial Panel on Multidistrict Litigation (“JPML”) centralized the Actions before this Court, *In re: Nat’l Prescription Opiate Litig.*, 2017 WL 6031547 (J.P.M.L. Dec. 5, 2017);

WHEREAS, the Court finds it has jurisdiction over the Actions centralized before this Court in this MDL No. 2804, and the parties to those Actions, for purposes of Settlement and asserts jurisdiction over the Settlement Class Representatives for purposes of considering and effectuating this Settlement; and

WHEREAS, this Court has considered all of the presentations and submissions related to the Motion, as well as the facts, contentions, claims, and defenses as they have developed in these proceedings, and is otherwise fully advised of all relevant facts in connection therewith;

NOW, THEREFORE, IT IS HEREBY ORDERED:

---

<sup>1</sup> “Teva” is defined here as set forth in Section I of the Class Action Settlement Agreement Among Third Party Payors and the Teva Defendants.

The proposed Settlement appears to be the product of intensive, thorough, serious, informed, and non-collusive negotiations; has no obvious deficiencies; does not improperly grant preferential treatment to the Settlement Class Representatives or segments of the Class; and appears to be fair, reasonable, and adequate, such that notice of the Settlement should be directed to Settlement Class Members and a Fairness Hearing should be set.

Accordingly, the Motion is GRANTED.

**I. CLASS DEFINITION, CLASS REPRESENTATIVES, AND CLASS COUNSEL**

“Class” or “Settlement Class” includes:

All entities that (i) paid and/or were reimbursed for Products manufactured, marketed, sold, distributed, or dispensed by any of the Defendants and/or Alleged Opioid Enterprise Members for purposes other than resale, and/or (ii) paid or incurred costs for treatment, services, or procedures related to the use of, misuse of, addiction to, and/or overdose from Products and other opioid drugs, on behalf of individual beneficiaries, insureds, and/or members, during the time period from January 1, 1996 to the date of entry of the Preliminary Approval Order. For clarity, the Class includes, but is not limited to: (a) private contractors of Federal Health Employee Benefits plans; (b) plans for self-insured local governmental entities that have not settled claims in MDL No. 2804; (c) managed Medicaid plans; (d) plans operating under Medicare Part C and/or D; (e) Taft-Hartley plans; and (f) ERISA plans. For the avoidance of doubt, all Plaintiffs identified in Exhibit B are included in the Class. Exhibit B is a non-exhaustive list and does not purport to identify all members of the Class.

Excluded from the Class are:

1. (a) all federal governmental entities and all state and local governmental entities whose claims have been released by a prior settlement with Teva, (b) PBMs; (c) consumers; and (d) fully insured plan sponsors. For the avoidance of doubt, entities that own an interest, even a controlling interest, in a PBM, are not excluded from the Class, unless they are otherwise excluded; and
2. (a) Teva and its subsidiaries, affiliates, and controlled persons; (b) officers, directors, agents, servants, or employees of Teva, and the immediate family members of any such persons; and (c)

persons and entities named as Defendants in any of the Actions coordinated under or Parallel to MDL No. 2804, unless such persons or entities are only Defendants due to a counter-claim or cross-claim by other Defendant(s).

Paul J. Geller, Elizabeth J. Cabraser, Mark J. Dearman, Eric B. Fastiff, and James R. Dugan, II, are hereby appointed as Interim Settlement Class Counsel, and Paul J. Geller, Elizabeth J. Cabraser, and James R. Dugan, II, are also hereby appointed as Interim Co-Lead Settlement Class Counsel, under Rule 23(g)(3) of the Federal Rules of Civil Procedure. Interim Co-Lead Settlement Class Counsel and Teva are authorized to take, without further Court approval, all necessary and appropriate steps to implement the Settlement, including the approved notice program.

The following TPP Plaintiffs are appointed as Settlement Class Representatives: Cleveland Bakers and Teamsters Health and Welfare Fund; Pipe Fitters Local Union No. 120 Insurance Fund; Pioneer Telephone Cooperative, Inc. Employee Benefits Plan; American Federation of State, County and Municipal Employees District Council 37 Health & Security Plan; Louisiana Assessors' Insurance Fund; United Food and Commercial Workers Health and Welfare Fund of Northeastern Pennsylvania; and Sheet Metal Workers Local No. 25 Health & Welfare Fund.

## **II. PRELIMINARY FINDINGS**

The Court is familiar with the standards applicable to certification of a settlement class. *See* Fed. R. Civ. P. 23(e); *Amchem Prods., Inc. v. Windsor*, 521 U.S. 591, 613 (1997); *Whitlock v. FSL Mgmt., LLC*, 843 F.3d 1084, 1093 (6th Cir. 2016) (analyzing the seven factors that govern the “fair, reasonable, and adequate” inquiry in the Sixth Circuit); Order Granting Plaintiff’s Unopposed Motion for Preliminary Approval of Settlement and Notice to Settlement Class, *Wiley v. TravelCenters of Am., LLC*, No. 1:21-cv-01093 (N.D. Ohio Aug. 25, 2022), ECF 19 (Polster, J.).

Applying these standards, the Court finds it will likely be able to certify, under Rule 23(e)(2), the proposed Settlement Class as defined above, for settlement purposes only, because the Class and its representatives likely meet all relevant requirements of Fed. R. Civ. P. 23(a) and (b)(3). In fact, the proposed settlement class is nearly identical to the TPP settlement class the Court previously certified. *See generally* Order Granting TPP Plaintiffs' Motion for Preliminary Approval of Class Action Settlement and Direction of Notice Under Federal Rule of Civil Procedure 23(e) (Sep. 3, 2024), ECF 5616; Final Order and Judgment Granting TPP Plaintiffs' Motion for Final Approval of Class Action Settlement, and Award of Attorneys' Fees and Expenses and Settlement Class Representative Service Awards (Jan. 15, 2025), ECF 5869.

### **III. NOTICE TO SETTLEMENT CLASS MEMBERS**

The Court is also familiar with evolving methods of class notice. As applied here, the Court finds the content, format, and method of disseminating Notice—set forth in the Motion (ECF 6600), the Joint Declaration of Paul J. Geller and Elizabeth J. Cabraser in support of the Motion (ECF 6600-1), and the exhibits attached thereto—satisfy Rule 23(c)(2) and contemporary notice standards. The Court approves the notice program and directs that notice substantially in the form of the Proposed Notice be disseminated in the manner set forth in the proposed Settlement and Motion, the Joint Declaration of Paul J. Geller and Elizabeth J. Cabraser, and the Declaration of Eric J. Miller to Settlement Class Members under Rule 23(e)(1). No later than fourteen (14) calendar days following the commencement of the dissemination of the Notice, Settlement Class Counsel shall serve on Teva and file with the Court proof, by affidavit or declaration, of such distribution.

**IV. PROPOSED SCHEDULE**

Interim Settlement Class Counsel propose the below schedule for disseminating Notice, filing objections to the Settlement, requesting exclusion from the Class, and filing TPP Plaintiffs' Motion for Final Approval and for Attorneys' Fees and Expenses:

<b>Event</b>	<b>Proposed Date</b> (unless specified otherwise, days herein are calendar days)	<b>Court-Adopted Date (if altered)</b>
Deadline for Teva to provide Class Action Fairness Act notice to appropriate federal and state officials.	10 days after the filing of the Settlement with the Court	Monday, June 22, 2026
Deadline for Notice and Claims Administrator to commence dissemination of Notice to Settlement Class Members via email and/or U.S. mail (the "Notice Date").	14 days following entry of Preliminary Approval Order	Monday, June 29, 2026
Deadline for Interim Settlement Class Counsel to serve on Teva and file with the Court proof, by affidavit or declaration, of the dissemination of the Notice.	14 days following the Notice Date	Monday, July 13, 2026
Deadline to submit opening briefs and supporting materials in support of Final Approval of Settlement and motion for attorneys' fees and expenses.	25 days after the Notice Date	Friday, July 24, 2026
Deadline for objectors to file Objections with the Court, and for Settlement Class Members to deliver written and signed Opt-Out Forms to Notice and Claims Administrator. For the avoidance of doubt, Opt-Out Forms must be received by Notice and Claims Administrator by such date.	45 days after the Notice Date	Thursday, August 13, 2026
Reply Memoranda in Support of Final Approval and Fee and Expense Application filed.	75 days after the Notice Date	Monday, September 14, 2026

<b>Event</b>	<b>Proposed Date</b> (unless specified otherwise, days herein are calendar days)	<b>Court-Adopted Date (if altered)</b>
<b>Fairness Hearing</b>	No earlier than the later of: (1) 100 days following submission of the Motion for Preliminary Approval; or (2) 5 days following Teva's deadline to exercise their Walk-Away Right.	Wednesday, September 23, 2026, at 12:00PM

The Fairness Hearing shall take place on Wednesday, **September 23, 2026**, at **12:00 p.m.** via zoom video conference before the Honorable Dan Aaron Polster, to determine whether the proposed Settlement is fair, reasonable, and adequate; whether it should be finally approved by the Court; and whether the Actions as to Teva and Released Claims should be dismissed with prejudice under the Settlement and the notice program. Any application for Attorneys' Fees and Expenses submitted by Interim Settlement Class Counsel and any application for a Service Award to the Settlement Class Representatives will be considered separately from the fairness, reasonableness, and adequacy of the Settlement.

#### **V. STAY OF ACTIONS AS TO TEVA**

The stay of all MDL No. 2804 TPP Actions as to Teva, including its subsidiaries and affiliates, shall continue until this Court has made its final settlement approval determination. The Court hereby severs and stays the Class Representatives' and TPP Bellwether Plaintiffs' cases as to Teva, including its subsidiaries and affiliates, during the same period. In aid of the Court's jurisdiction over this Action, all Settlement Class Members are hereby enjoined from filing, commencing, prosecuting, continuing, litigating, intervening in, or participating as class members in any action asserting Released Claims against any Released Entities in any forum or jurisdiction, unless and until such Settlement Class Member has timely excluded itself from the Settlement Class.

**VI. PROCEDURE FOR OPT-OUTS AND OBJECTIONS**

The procedure for Opt-Outs set forth in Section V.G. of the Settlement Agreement, and the instructions in the Notice regarding the procedures that must be followed to opt out of the Settlement Class and Settlement, as set forth in the Settlement Agreement and proposed Notices attached thereto, are approved. Opt-Out forms must be received by the Notice and Claims Administrator no later than the date designated for such purpose in the Notice and set forth in the chart above.

No “mass,” “class,” “group,” or otherwise combined Opt-Out Forms shall be valid, and no entity may submit an Opt-Out Form on behalf of any other entity that is included in the Class definition including, but not limited to, subsidiaries, affiliated or related companies or business entities, divisions, partnerships, or joint ventures, clients, customers, or administrative services organization.

Any Settlement Class Member that does not submit a timely and valid Opt-Out Form in accordance with Section V.G. of the Settlement Agreement submits to the jurisdiction of the Court and, unless the Settlement Class Member submits an Objection that complies with the provisions of Section V.F., shall waive and forfeit any and all Objections to the Settlement or the Agreement the Class Member may have asserted.

The procedure for Objections to the Settlement or to an award of fees or expenses to Settlement Class Counsel, as set forth in Section V.F. of the Settlement Agreement, is approved.

The assertion of an Objection does not operate to opt the TPP asserting it out of, or otherwise exclude that TPP from, the Settlement Class. A TPP within the Settlement Class can opt out of the Settlement Class and Settlement only by submitting a valid and timely Opt-Out Form in accordance with the Settlement Agreement and this Order.

No later than seven (7) calendar days following the deadline set by the Court for Settlement Class Members to opt out from the Class, Interim Settlement Class Counsel shall direct and the Notice and Claims Administrator shall provide Teva's counsel with the Opt-Out Report identifying all requests to be excluded from the certified Class, and whether any such requests were deemed untimely and/or failed to provide any of the information required in Section V.G.1. of the Settlement Agreement or were otherwise inadequate.

Pursuant to Section VI.C.2. of the Settlement Agreement, Teva may, in its sole discretion, terminate the Agreement by serving written notice, by email and overnight courier, to Interim Settlement Class Counsel within fifteen (15) calendar days following receipt by Teva from Interim Settlement Class Counsel of the Opt-Out Report (the "Walk-Away Right"), unless such date is extended by mutual agreement of Interim Settlement Class Counsel and Teva.

**VII. SETTLEMENT ADMINISTRATION, NOTICE, AND CONTINUING JURISDICTION**

The dates and deadlines set forth in this Preliminary Approval Order, including, but not limited to, the Fairness Hearing, may be extended by Order of the Court without further notice to Settlement Class Members, except that notice of any such extensions shall be included on the Settlement website. Settlement Class Members should check the Settlement website regularly for updates and further details regarding extensions of these deadlines. Opt-Out Forms and Objections must meet the deadlines and follow the requirements set forth in the approved Notice in order to be valid.

Interim Co-Lead Settlement Class Counsel and Teva are hereby authorized to use all reasonable procedures in connection with approval and administration of the Settlement not materially inconsistent with the Preliminary Approval Order or the Settlement Agreement, including making, without further approval of the Court, minor changes to the Settlement Agreement, the form or content of the Notice, or any other exhibits the Settlement Class

Representatives and Teva jointly agree are reasonable or necessary, except as otherwise provided in the Settlement Agreement.

The Court appoints A.B. Data, Ltd. to serve as the Notice and Claims Administrator, and authorizes A.B. Data, Ltd., through data aggregators or otherwise, to request, obtain, and use Settlement Class Members' information for notice purposes.

Settlement Class Members that wish to participate in the Settlement shall complete and submit Claim Forms in accordance with the instructions contained therein. Unless the Court orders otherwise, all Claim Forms must be submitted no later than **December 1, 2026**. Any Settlement Class Member that submits a Claim Form shall reasonably cooperate with the Notice and Claims Administrator, including by promptly responding to any inquiry made by the Notice and Claims Administrator. Any Settlement Class Member that does not timely submit a Claim Form within the time provided shall be barred from sharing in the distribution of the proceeds of the Settlement but shall nonetheless be bound by the Settlement Agreement, the Final Judgment, and the releases therein, unless otherwise ordered by the Court. The Claim Form shall comply with the requirements set forth in the Settlement Agreement and any further requirements described in the form attached as Exhibit C to the Settlement Agreement.

The Court appoints Citibank, N.A. as Escrow Agent, which shall control and administer an Escrow Account to be established as set forth in the Settlement. Within the later of twenty-one (21) calendar days of the entry of this Order or Teva's receipt of information and instructions required to effectuate a wire transfer in satisfaction of this paragraph, Teva shall pay by wire transfer a portion of the Settlement Amount sufficient to cover the Notice and Administrative Costs, and any Taxes and Tax Expenses as they become due, but in no event greater than \$1,000,000.00. The Escrow Agent may direct payment of up to \$1,000,000.00 for reasonable Notice and Administrative Costs, including Taxes or Tax Expenses, as approved by this Court.

Any portion of the Escrow Account not used for Notice and Administrative Costs and Taxes or Tax Expenses paid, incurred, or due and owing shall be returned to Teva, including interest accrued, if, for any reason, the Effective Date does not occur.

All funds held by the Escrow Agent shall be deemed and considered to be in *custodia legis* of the Court, and shall remain subject to the jurisdiction of the Court, until such time as such funds are distributed pursuant to the Settlement and/or further order(s) of the Court.

The Court also authorizes that the Escrow Account be established as a “qualified settlement fund” within the meaning of Treasury Regulations §1.468B-1 (and corresponding or similar provisions of state, local, or foreign law, as applicable). Such account shall constitute the Qualified Settlement Fund as defined in the Settlement Agreement.

The Court shall maintain continuing jurisdiction over these proceedings (including over the administration of the Qualified Settlement Fund) for the benefit of the Settlement Class.

Neither this Preliminary Approval Order, the Settlement, nor any of its terms or provisions, nor any of the negotiations or proceedings connected with it, shall be considered, construed, or represented to be: (1) an admission, concession, or evidence of liability or wrongdoing; or (2) a waiver or any limitation of any defense otherwise available to Teva.

If the Settlement is not approved or consummated for any reason whatsoever, the Settlement and all proceedings had in connection therewith shall be without prejudice to the rights of the Settling Parties *status quo ante* as of January 1, 2026, as set forth in Section V.C.2. of the Settlement Agreement, except as otherwise expressly provided in the Settlement Agreement. In such event, Teva will not be deemed to have consented to certification of any class, and will retain all rights to oppose, appeal, or otherwise challenge, legally or procedurally, class certification or any other issue in the Actions. Likewise, if the Settlement does not reach Final Judgment, then the participation in the Settlement by any Settlement Class Representative or Settlement Class Member cannot be raised

as a defense to their claims.

**IT IS SO ORDERED.**

DATED: June 18, 2026

*s/Dan Aaron Polster*  
THE HONORABLE DAN A. POLSTER  
UNITED STATES DISTRICT JUDGE